CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index; 9 of the 17 sources its claims cite were checked for support.
Abstract
BACKGROUND: . METHODS: After conducting preclinical in vitro and in vivo studies, we evaluated the safety and pharmacodynamic effects of single escalating doses of NTLA-2001 in six patients with hereditary ATTR amyloidosis with polyneuropathy, three in each of the two initial dose groups (0.1 mg per kilogram and 0.3 mg per kilogram), within an ongoing phase 1 clinical study. RESULTS: after a single dose. Serial assessments of safety during the first 28 days after infusion in patients revealed few adverse events, and those that did occur were mild in grade. Dose-dependent pharmacodynamic effects were observed. At day 28, the mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the group that received a dose of 0.1 mg per kilogram and was 87% (range, 80 to 96) in the group that received a dose of 0.3 mg per kilogram. CONCLUSIONS: . (Funded by Intellia Therapeutics and Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT04601051.).
Overview
CoChat Summary
TL;DR
In six patients with hereditary ATTR amyloidosis with polyneuropathy, single intravenous doses of NTLA-2001, a CRISPR-Cas9 lipid nanoparticle therapy, produced dose-dependent reductions in serum TTR protein at day 28 and only mild adverse events. This interim phase 1 study provides early clinical proof of concept for in vivo CRISPR-Cas9 gene editing.
Key findings
- At day 28, mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the 0.1 mg/kg group and 87% (range, 80 to 96) in the 0.3 mg/kg group.
- Adverse events occurred in three of six patients and were all grade 1 (mild); no serious adverse events were observed. One patient had a grade 1 infusion-related reaction, and increased d-dimer levels in five of six patients returned to baseline by day 7.
- Preclinical studies showed durable TTR knockout after a single dose: in primary human hepatocytes, NTLA-2001 had EC50 0.05 to 0.15 nmol/L and EC90 0.17 to 0.67 nmol/L, with ≥93.7% TTR editing and ≥95% reduction in TTR protein production; in cynomolgus monkeys, a single dose of Cyn-LNP at 3 or 6 mg/kg produced maximum whole-liver gene editing of 73% and >94% reduction in serum TTR protein sustained over 12 months.
Methods
- Interim results from two initial dose groups of a two-part, global, phase 1, open-label, multicenter study: six patients with hereditary ATTR amyloidosis with polyneuropathy received a single intravenous dose of NTLA-2001 at 0.1 mg/kg or 0.3 mg/kg (three patients each) between November 2020 and April 2021.
- Key eligibility included age 18 to 80 years, polyneuropathy due to hATTR amyloidosis with or without cardiomyopathy, body weight 50 to 90 kg, and lack of access to approved ATTR treatments; prior TTR stabilizers were permitted after washout.
- Serum TTR protein was measured by validated enzyme-linked immunosorbent assay at baseline and weeks 1, 2, and 4; analyses were descriptive, comparing baseline with day 28 as mean percentage change and range. Preclinical work included primary human hepatocytes, transgenic mice, and cynomolgus monkeys.
Limitations
- The paper states that the study involves a very small number of patients with limited follow-up to date, and that continued serial measurements are planned to confirm durability. It also states that these are interim results from the first two dose groups in an ongoing dose-escalation study.
- Evident from the text: the clinical portion is open-label with no control group, uses descriptive analyses only, reports safety and pharmacodynamic effects through day 28, and does not report clinical outcomes such as disease progression, quality of life, or mortality.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
7 Valid · 1 Not valid · 5 Not checked · 56 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“TTR, which has a normal physiological role in vitamin A transport. 31”
What the sources say
- Supportedcites [31] 31. Müller ML, Butler J, Heidecker B. Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy? Eur J Heart Fail 2020; 22: 39-53. source
The Introduction states that TTR physiologically transports retinol-binding protein. The Therapeutic antisense oligonucleotides section links this function to vitamin A levels, supporting the paraphrase that TTR normally plays a role in vitamin A transport. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“but are limited by the requirement for long-term administration to maintain TTR knockdown.”
What the sources say
- Partly supportedcites [12] 12. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21. sourceExperimental — accuracy not yet measured
The Trial Design and Regimens section reports patisiran infusions every three weeks for 18 months, and Pharmacodynamics reports sustained TTR reduction during that period. The paper does not establish that long-term administration is required to maintain knockdown after treatment stops, or that this limitation applies to current ATTR treatments generally. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [13] 13. Adams D, Polydefkis M, GonzálezDuarte A, et al. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an openlabel extension study. Lancet Neurol 2021; 20: 49-59. source
- Partly supportedcites [14] 14. Solomon SD, Adams D, Kristen A, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 2019; 139: 431-43. sourceExperimental — accuracy not yet measured
The Methods (Study Design and Treatment; page unavailable) report patisiran infusions every three weeks for 18 months, and the introductory passage describes its reduction of TTR protein. The paper does not establish that long-term administration is required to maintain TTR knockdown or characterize that requirement as a limitation of current ATTR treatments generally. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“More extensive TTR knockdown is associated with greater improvement in neuropathic end points in patients with hATTR polyneuropathy. 12”
What the sources say
- Partly supportedcites [12] 12. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21. sourceExperimental — accuracy not yet measured
The Primary End Point section reports a correlation between the degree of TTR reduction and change in mNIS+7, a composite neuropathy measure, at 18 months. The paper reports improvements in other end points, but our copy does not link the extent of knockdown to improvement across those end points. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“circulating TTR is produced almost entirely (>99%) within the liver, 2”
What the sources say
- Partly supportedcites [2] 2. Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 2015; 66: 2451-66. sourceExperimental — accuracy not yet measured
The section labeled “Diagnosis and Classification” says TTR is synthesized primarily in the liver, supporting the liver as its main source. It does not give the claimed >99% figure for circulating TTR. No page number is available in our copy. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Inotersen is associated with serious side effects, including glomerulonephritis and decreased platelet counts. 17”
What the sources say
- Supportedcites [17] 17. Gertz MA, Scheinberg M, Waddington-Cruz M, et al. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-medi- - ated amyloidosis. Expert Rev Clin Pharmacol 2019; 12: 701-11. source
The Safety and tolerability section (p. 9) reports decreased platelet counts and glomerulonephritis in patients receiving inotersen, including severe cases. The Regulatory affairs section (p. 9) states that the US approval carries a black box warning for increased risks of thrombocytopenia and glomerulonephritis. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
43 more claims · 1 with their cited sources checked
Create a free account to see all 69 claims and every source verdict.
- Probably not a substantial claim. 11
- It may state two separate claims as one. 15
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“which has already lead to investigational new drugs in clinical trials (NCT04601051)”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Gillmore et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“Ionizable lipid nanoparticles (LNPs) are a promising non-viral delivery platform for mRNA nanomedicines (13, 14) that have been used to deliver siRNA and CRISPR-based gene editing therapies to the liver in postnatal mouse, non-human primate, and clinical studies with encouraging results (15–18).”
From Ionizable Lipid Nanoparticles for Therapeutic Base Editing of Congenital Brain Disease (2023) · cites this paper as [17]
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805689 · Cited by 2,857
Bae, S., Park, J., & Kim, J.-S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu048 · Cited by 2,339
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3117 · Cited by 2,268
Li, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0089-y · Cited by 1,715
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Benson, M. D., Waddington-Cruz, M., Berk, J. L., Polydefkis, M., Dyck, P. J., Wang, A. K., Planté-Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,452
Self-citationCRISPR–Cas9 genome editing induces a p53-mediated DNA damage response
Haapaniemi, E., Botla, S., Persson, J., Schmierer, B., & Taipale, J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0049-z · Cited by 1,264
Cited by
Items 1,501–1,600 of 1,725
Paradigm shift in life science research: challenges and <?A3B2 pi6?>coping strategies
Zhang, H. (2025) · Scientia Sinica Vitae · doi:10.1360/ssv-2024-0339
Therapeutic Applications of Genome Editing Tools for Genetic Diseases
Park, J.-C., & Bae, S. (2025) · Journal of Electrodiagnosis and Neuromuscular Diseases · doi:10.18214/jend.2024.00073
“…body to treat hereditary transthyretin amyloidosis with polyneuropathy (hATTRv-PN) and hereditary transthyretin amyloidosis with cardiomyopathy (hATTR-CM) [11]. hATTR is an autosomal dominant, adult-onset genetic disease caused by mutations in TTR , which encodes the transthyretin protein [12,13].”
Ефимов, И. В., Anisimova, P. V., Shibzukhov, A. A., et al. (2025) · Vestnik nevrologii psihiatrii i nejrohirurgii (Bulletin of Neurology Psychiatry and Neurosurgery) · doi:10.33920/med-01-2504-08
New Frontiers and Evolving Therapies in ATTR Cardiac Amyloidosis
Wardhere, A., Bampatsias, D., & Maurer, M. S. (2025) · Springer eBooks · doi:10.1007/978-3-031-88342-2_15
Zheng, Z., Yu, M., Ai, L., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-4552906/v1
Gene Therapy & Gene-Editing Techniques
LaRocca, C. J., & Steer, C. J. (2025) · Success in academic surgery · doi:10.1007/978-3-031-83034-1_13
CRISPR Therapies for Alzheimer’s Disease
Sun, J., & Roy, S. (2025) · Springer eBooks · doi:10.1007/978-3-031-89307-0_12 · Cited by 1
Lu, J., Gao, Y., Li, Q., Jiao, Y., Bian, Y., Lin, H., Lei, X., Wang, W., Li, Z., & Wang, L. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104867 · Cited by 1
Pagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2025) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2025.08.006
Li, L. (2024) · The Conversation · doi:10.64628/aai.c5xr6pjq5 · Cited by 2
The Evolving Landscape of Amyloid Research
Bonilauri, B. (2025) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.70048
Advances in viral and nonviral delivery systems for therapeutic gene editing
Jiang, W., Jeong, H. C., & Kim, J. H. (2025) · Taiwan Journal of Ophthalmology · doi:10.4103/tjo.tjo-d-25-00068
Yu, T., Wang, Y., Kong, Y., Wang, J., Hong, Y., Wang, Y., Hu, F., Zhu, Z., & Yuan, H. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202501497 · Cited by 3
Developing therapeutics for rare cardiovascular diseases
Lerman, J. B., Koeberl, D. D., Epstein, S., Roessig, L., Stan, R., Halley, M. C., OWENS, A. T., Greenberg, B., Alexander, K. M., Day, S. M., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.09.004
Kramer, C. M., Fry, E. T. A., & Morris, P. B. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.026
Nanodelivery in Gene Therapy: Unlocking the Potential for Precision Medicine
Eksi, O. B., Kutlu, A. Ü., Yumuk, K., Memet, B. C., Benk, R., Kurşunluoğlu, G., & Aydin, Ö. F. (2025) · Springer eBooks · doi:10.1007/978-3-032-00773-5_410
40 ans de biotechnologies: Que sont les enfants de Tom Maniatis devenus ?
Pagès, J. (2025) · médecine/sciences · doi:10.1051/medsci/2025124
Shimizu, R., Kashiwakura, Y., Hayakawa, M., Kita, S., Sato, M., Maeki, M., Tokeshi, M., Maenaka, K., Ohmori, T., Yamada, Y., et al. (2025) · RSC Pharmaceutics · doi:10.1039/d5pm00189g
Vera, A. O., Avilés-Vázquez, F. J., Ha, T., Choudhary, A., & Raines, R. T. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.5c19089
Historia, diagnóstico y tratamiento de la amiloidosis cardíaca por transtiretina: una revisión
Antoniutti, G. (2025) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2025.10.003
Genetic Perturbation Modeling for Human Cell Therapy With BRNET
Cai, L., Yu, J., Lin, Q., Liu, L., Li, X., & Wong, K. (2025) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2025.3629554
“Transcriptional profiling facilitates the identification of genetic interactions, significantly advancing the development of combination therapies [4], [5], [6], [7] and enabling precise cell engineering [8], [9], [10], [11], [12], [13].”
Transthyretin amyloid cardiomyopathy
Fensman, S. K., Mejren, A. H. J., Clemmensen, T. S., et al. (2025) · Ugeskrift for Læger · doi:10.61409/v04250323
Emerging Targeted Therapies for Inherited Cardiomyopathies and Arrhythmias
Ryan, T. L., & Roberts, J. D. (2025) · Heart Failure Clinics · doi:10.1016/j.hfc.2025.08.004
Epigenetic Regulation of Neuroinflammatory and Autophagic Pathways
Dey, Y. N., Pramanik, S. D., Roy, P., Ganguly, A., & Samanta, S. K. (2025) · Springer eBooks · doi:10.1007/978-981-95-3945-1_7
Zaklyazminskaya, E. V. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33927-1.00014-6 · Cited by 1
Phosphonate-based amphiphiles for nucleic acid delivery
Roux, C. L., Berchel, M., & Jaffrès, P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33374-3.00036-0
Chordin-Like 1 mRNA Therapy for Acute Myocardial Infarction
Tomczyk, M., Kraszewska, I., Li, G., Hayes, M. J., Venditti, L., Huntington, J., Wong, C. K., Cadoni, A., Bortolotti, F., Mura, A., et al. (2025) · Circulation · doi:10.1161/circulationaha.125.074078 · Cited by 1
Keskinen, T., Jalil, S., Gümüşoğlu, I. I., Juutila, J., Kestilä, N., Kuuluvainen, E., Hietakangas, V., Balboa, D., Wartiovaara, K., & Hyvönen, M. E. (2025) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.70122
Cardiac amyloidosis: a clinical and pathological review
Maleszewski, J. J. (2025) · Diagnostic histopathology · doi:10.1016/j.mpdhp.2025.11.001
Sun, C., Xu, Y., & Luo, T. (2025) · Materials Today Communications · doi:10.1016/j.mtcomm.2025.114507 · Cited by 1
Self-citationDeneault, É. (2025) · Genetics. · doi:10.5772/intechopen.1013143 · Cited by 1
Investigating and correcting a rare pathogenic mutation in GDF11
Congdon, S. T., Bennett, J. E., Opinya, R., Agosto, A. R., Dossias, O., Kokko, C., Levesque, A. A., Koob, A. O., Silver, A. C., & Thomas-Charles, C. A. (2025) · Human Genetics and Genomics Advances · doi:10.1016/j.xhgg.2025.100559
Kwon, J., Kim, M., Hwang, W., Jo, A., Hwang, G.-H., Jung, M., Kim, U. G., Cui, G., Kim, H. S., Eom, J.-H., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22601900
Im, S. H., Jang, M., Park, J.-H., & Chung, H. J. (2024) · Figshare · doi:10.6084/m9.figshare.25596399
Bloszyk, J., Stachowiak, M., & Halliday, B. (2006) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.172508
Kwon, J., Kim, M., Hwang, W., Jo, A., Hwang, G.-H., Jung, M., Kim, U. G., Cui, G., Kim, H. S., Eom, J.-H., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22601891
Zhao, J.-J., Sun, X.-Y., Tian, S.-N., Zhao, Z.-Z., Yin, M.-D., Zhao, M., Zhang, F., Li, S.-A., Yang, Z.-X., Wen, W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25239456
Kwon, J., Kim, M., Hwang, W., Jo, A., Hwang, G.-H., Jung, M., Kim, U. G., Cui, G., Kim, H. S., Eom, J.-H., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22601906
Zhao, J.-J., Sun, X.-Y., Tian, S.-N., Zhao, Z.-Z., Yin, M.-D., Zhao, M., Zhang, F., Li, S.-A., Yang, Z.-X., Wen, W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25239409
Kwon, J., Kim, M., Hwang, W. C., Jo, A., Hwang, G.-H., Jung, M., Kim, U. G., Cui, G., Kim, H. S., Eom, J.-H., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22601897
Sandhya, S., Prakash Goudanavar, S. O. P., & Naik, P. (2025) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-025-10779-y
“The fact that this gene-edited drug was tested on humans for the first time, and only mild adverse effects were reported, lends credence to its safety and effectiveness (Gillmore et al. 2021).”
mRNA-based vaccines: Rational antigen design, delivery optimization, and immune modulation
Liu, S., Shi, H., Dai, D., Tian, T., Duan, X., Sun, J., Xu, W., Yin, X., Xie, Y., & Song, X. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.112312
Nanomaterials for Gene Therapy in Animal Health
Bathla, S. (2026) · Smart nanomaterials technology · doi:10.1007/978-981-95-4542-1_6
Biopharmaceutical Production from Cell Engineering and Molecular Pharming
Mishra, A., Malik, A., Marwal, A., & Gaur, R. K. (2026) · Springer eBooks · doi:10.1007/978-981-95-3823-2_5
Biopolymers: The Next Frontier in Therapeutics
Hussain, N., Ijaz, H., Amjad, Z., Arooj, R., Khan, W. A., Malik, H. A., Munawar, A., & Laila, U. (2026) · Advanced structured materials · doi:10.1007/978-981-95-2469-3_12
CRISPR-Cas9 Technology for Combating Genetic Disorders
Sharma, A. K., & Singh, P. (2026) · IGI Global eBooks · doi:10.4018/979-8-3373-4857-5.ch005
CRISPR-Cas9 Technology in Regenerative Medicine and Tissue Engineering
Gunasekaran, A., Vanaraj, M., Kumar, M. S. P., Abidharini, J. D., Boro, A., Philomenathan, A. P. J., Asirvatham, A. R., & Arumugam, V. A. (2026) · IGI Global eBooks · doi:10.4018/979-8-3373-4857-5.ch006
CRISPR-Cas9 Technology for Unlocking Immunity Against Infectious Pathogens
Suriya, M., Aarthi, V., Meenambiga, S. S., Prakash, P. R., & Vivek, P. (2026) · IGI Global eBooks · doi:10.4018/979-8-3373-4857-5.ch003
Tahir, A. M., Imtiaz, E., Ali, F. Z., et al. (2026) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000004709
“The pivotal Phase 1 study of the investigational CRISPR therapeutic NTLA-2001 in ATTR amyloidosis showed rapid, deep, and durable serum TTR declines exceeding 85–90% by day 28, with symptomatic alleviation and encouraging cardiological results in majority of treated patients [ 3 ] .”
Chen, Z., Yang, J., Zheng, B., Yang, Y., Qiu, X., Zhou, H., Wang, R., & Xiong, H. (2026) · Angewandte Chemie · doi:10.1002/ange.202523579
Future of Regenerative Hepatology
Martínez-García, J., Blanes-Rodríguez, Á., Barbancho, S. M., Viartola, M. S., & Baptista, P. M. (2026) · Springer eBooks · doi:10.1007/978-3-032-10997-2_23
Ahamed, J., Khanna, S., Siddiqua, A., Wahab, S., Gupta, G., Goh, K. W., & Kesharwani, P. (2026) · Microchemical Journal · doi:10.1016/j.microc.2026.117039
Lu, Z., Bukhari, S. T. H., Azeem, M., Tariq, N., & Shabbir, M. A. B. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1737251 · Cited by 3
“As a result, recent studies and initial clinical trials principally involve somatic gene editing, which marks non-reproductive cells and does not involve mechanisms of heredity (119, 120).”
Updates on hereditary transthyretin amyloidosis polyneuropathy
Wang, T.-W., Hsueh, S., Hsueh, H., Hsieh, S., & Chao, C. (2026) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2026.01.023 · Cited by 1
Bibliometric Insights into CRISPR-Cas9 Research Targeting Human Disease Pathology
Sweileh, M. W. (2026) · SAGE Open · doi:10.1177/21582440261415669
“Soon after this, research on CRISPR-Cas9 moved from basic science to clinical application in various disciplines especially genetic disorders (Frangoul et al., 2021; Germino-Watnick et al., 2022; Gillmore et al., 2021).”
CRISPR-Based Synthetic Gene Circuits for Industrial and Therapeutic Applications
Raue, J. M. (2024) · Academic International Journal of Engineering Science · doi:10.59675/e224
“CRISPR systems have been used in gene therapy to repair genetic pathogen mutations in genetic disease treatments such as sickle cell anemia, beta-thalassemia, and Duchenne muscular dystrophy with a number of therapeutic candidates successfully passing through clinical development stages [47, 48].”
Transthyretin Amyloid Cardiomyopathy: A Rapidly Evolving Landscape
Zeldin, L., Brailovsky, Y., & Maurer, M. S. (2026) · Annual Review of Medicine · doi:10.1146/annurev-med-050124-030735 · Cited by 1
Shibah, S. R. M. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.6122246
Bio-orthogonal chemistry-based strategy to Turn-OFF CRISPR-Cas9 activity in solution and live cells
Pandit, B., Vangaveti, S., Sentre, J. F., McClain, I. M., Fuchs, G., & Royzen, M. (2026) · NAR Molecular Medicine · doi:10.1093/narmme/ugag008 · Cited by 1
“Many ongoing clinical trials utilize lipid nanoparticles (LNPs) to co-deliver the two gene-editing components [ 8 , 9 ].”
A Cautionary Tale: An Instructive Case of Recognising Non‐Amyloid Light Chain Renal Amyloidosis
Bimal, G., Lee, D., Hosking, P., et al. (2026) · Nephrology · doi:10.1111/nep.70170
Targeted nanodelivery of CRISPR/Cas9 for hepatocellular carcinoma gene therapy in murine models
Yue, F., Jiang, X., Yang, Y., Jiang, Y., Ma, L., Wang, F., & Luo, J. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.173751 · Cited by 2
Solé, G., Duval, F., Beauvais, D., & Espil-Taris, C. (2026) · Pratique Neurologique - FMC · doi:10.1016/j.praneu.2026.01.007
mRNA Technology Beyond Vaccines: Exploring Potential mRNA-Based Therapies for Autoimmune Diseases
Kharat, M. G., Kulkarni, V. A., Chavan, S. P., Gawali, N. B., & Khandarkar, S. M. (2026) · Asian Journal of Pharmaceutical Research · doi:10.52711/2231-5691.2026.00001
Synergistic integration of inducible RNA switches enhances the manipulation of vector expressionPreprint
Zhang, Y., Yang, Y., Liu, Z., Li, Y., Xue, Y., Zhang, Z., Chen, G., Lu, T., Zhang, Y., Zhao, D., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.06.704328
Kim, T. K., & Hinson, J. T. (2026) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001278 · Cited by 1
Status and outlook of mRNA therapeutics for viral diseases
Pan, Q., Wang, W., Hl, J., & Zhong, Z. (2026) · EMBO Molecular Medicine · doi:10.1038/s44321-026-00390-z
“Collectively, these studies underscore the potential of CRISPR-based antivirals as highly adaptable and sequence-speci fi c therapeutic modalities, with early-phase clinical trials of mRNA – LNP – delivered CRISPR/Cas systems currently underway (Flight et al, 2025; Gillmore et al, 2021) (Table 2).”
Masi, G., Alvisi, G., Nespeca, P., Demarinis, A., Frasson, C., Barzon, L., Barbaro, V., Ferrari, S., Palù, G., Iorio, E. D., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.09.704349 · Cited by 1
Virus-like particle delivery enables orthogonal genome editing in vitro and in vivoPreprint
Shin, S., Nam, B.-G., Park, E. J., Kim, M. G., Cho, C. S., Kim, Y.-W., Lee, S., Kim, J. H., & Sangsu, B. A. E. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.10.705092 · Cited by 2
Yuan, X., Lv, Y., Wang, X., et al. (2026) · Frontiers in Genetics · doi:10.3389/fgene.2026.1715134
“NTLA-2001, delivered via lipid nanoparticles, induces permanent TTR gene disruption, achieving up to 95% reduction in serum TTR levels after a single infusion with an acceptable safety profile (Gillmore et al., 2021).”
Kamanu, C., Dutta, S., Patel, A., & Brailovsky, Y. (2026) · Springer eBooks · doi:10.1007/978-3-032-12626-9_17
Siles, L., Ruiz-Nogales, S., Méndez-Vendrell, P., & Pomares, E. (2026) · Cells · doi:10.3390/cells15050457
“Particularly, lipid nanoparticles (LNPs) have shown promising results in ongoing clinical trials for CRISPR delivery in non-ocular diseases [21–23].”
mRNA therapy: A novel approach for retinal neurodegenerative diseases
Zhang, B., Tang, J., Zhang, Q., Qiu, Y., Cheng, Y., Yu, S., Liu, L., Xue, J., Liu, X., He, Q., et al. (2026) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-01306 · Cited by 3
CRISPR/Cas in sea lamprey: new tools for functional genomics and genetic control
Sarasamma, S., & Li, W. (2026) · Reviews in Fish Biology and Fisheries · doi:10.1007/s11160-026-10045-4 · Cited by 3
Wang, L., Zhang, S., 仲巍, Zhu, K., Yang, Q., Ma, Z., & Li, J. (2026) · Journal of Bioethical Inquiry · doi:10.1007/s11673-025-10521-9 · Cited by 1
In Vivo Blood Kinetics and Transcript Integrity of Three mRNA–Lipid Nanoparticle Vaccines in HumansPreprint
Kent, S. J., Li, S., Amarasena, T. H., et al. (2026) · medRxiv · doi:10.64898/2026.03.13.26348310
CRISPR-Cas9: Genome Engineering and Future Vaccine Applications
Madhi, M., & Gholizadeh, P. (2026) · Molecular Biotechnology · doi:10.1007/s12033-026-01563-4 · Cited by 2
“Their clinical utility has been further demonstrated by the successful in vivo delivery of CRISPR-Cas9 mRNA for therapeutic gene editing [45].”
InfluentialGene Therapy for Heart Failure
Thoonkuzhy, T., & Eisen, H. J. (2026) · Springer eBooks · doi:10.1007/978-3-032-12629-0_16
Thalib, H. I., Khan, S., Shaikh, A. H., Alawi, K. M., Alabdrabalrasol, Z. H., Mehveen, S., Haidar, S., Hassan, F. E., & Shaik, N. A. (2026) · Genetic Testing and Molecular Biomarkers · doi:10.1177/19450265261434900
“…the practical translation of these fi ndings is supported by advanced delivery approaches, including AAV serotypes (notably AAV6 and AAV9) and lentiviral vectors employed in several included studies, paralleling strategies associated with clinical-stage gene editing research (Gillmore et al., 2021).”
Sahel, D. K., Tiyaboonchai, A., Wakefield, L., Renner, J., Jozić, A., Dorrell, C., Vlasova, K. Y., Murthy, N. T. V., Grompe, M., & Sahay, G. (2026) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2026.102933
Evolving Strategies in Cardiac Amyloidosis
Stein-Merlob, A. F., Swier, R. M., & Vucicevic, D. (2026) · Heart Failure Clinics · doi:10.1016/j.hfc.2025.11.005
Efficient Microinjection and CRISPR/Cas9 Mediated Genome Editing in Urechis unicinctus
Wang, K., Chen, J., Bai, S., Wang, Q., Zhang, W., Qin, Z., Zhang, Z., Zhang, Z., & Ma, Y. (2026) · Marine Biotechnology · doi:10.1007/s10126-026-10702-6
Horwacik, J., Maligłówka, M., Bułdak, Ł., & Okopień, B. (2026) · Livers · doi:10.3390/livers6020025
“The LNP-based delivery system directly targets hepatocytes, in which NTLA-2001 is supposed to correct the TTR gene, inhibiting the production of wild-type and mutant proteins [174].”
Formulation Screening of Lipid Nanoparticles Enhances mRNA Delivery to Retina
Yu, J., Ma, Z., Tong, H., Li, Y., Li, D., Zhu, Q., Shi, H., Zhou, L., Tian, C., Li, B., et al. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01760
Swine reporter model for preclinical evaluation and characterization of gene delivery vectors
Campbell, J. M., Korpela, D. M., Han, H., Zhao, S., Webster, D. A., Nguyen, Y. A. H., Koes, N., Aune, R., Dagan, H., Milliken, R., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201729
Stambolsky, D. V., Zakharova, A. V., & Karagyaur, M. N. (2026) · Регенерация органов и тканей. · doi:10.60043/2949-5938-2025-1-10-21
Gardin, A. (2023) · theses.fr (ABES) · doi:10.70675/ac839ccez52b2z45bez9294ze72731823d9b · Cited by 1
Vectorisation d'ARN par voie orale et parentérale
Stalder, T. (2024) · theses.fr (ABES) · doi:10.70675/d509592fzbb96z4f17zb286z5040de22fd65
Essays on Innovation Diffusion
Verluise, C. (2022) · theses.fr (ABES) · doi:10.70675/0cfcaa37z31eaz473ezb219z8d18ab21d9c8
Etude des réponses T CD8+ après transfert de gène par rAAV ciblant le muscle
Jeanpierre, L. (2024) · theses.fr (ABES) · doi:10.70675/430aceacz50d2z426bz907dz876c55d1e935
Li, Y., Ma, S., & Fei, T. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083371 · Cited by 1
Enhanced Intracellular Stability and Translation Efficiency of mRNA Drugs by a 2‐arm mRNA Platform
Teng, X., Lin, J., Zhang, Q., Zhang, X., Dai, Y., & Li, J. (2026) · Advanced Science · doi:10.1002/advs.75244
Next-Generation Therapies for Genetic Diseases: The Synergy of CRISPR and Gene Therapy
Karwa, P. N., Kharul, A., Parekar, V., Labhade, S., Sakle, N. S., Bhole, R. P., & Kapare, H. S. (2026) · Biochemical Genetics · doi:10.1007/s10528-026-11378-2 · Cited by 1
Ethical Principles in Cardiovascular Research
Zaidi, D., Dickert, N. W., Gireesh, A., Dudzinski, D. M., & Silverman, B. C. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-15734-9.00090-x
Peptide–Lipid Nanoparticles Enhance Cell Transfection Efficiency
Ye, Y., Hu, H., Yue, L., Su, R., Qi, W., & Wang, Y. (2026) · Langmuir · doi:10.1021/acs.langmuir.5c05962
Gene Editing for Haemophilia—The Next Frontier
Pinotti, M., Newby, G. A., Selvaraj, S. R., & Pipe, S. W. (2026) · Haemophilia · doi:10.1111/hae.70238 · Cited by 1
Nanoparticle-Enabled CRISPR/Cas Systems for Diagnostics and Therapeutics
Yi, K., Kong, H., Tao, Y., & Li, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-34203-5.00020-6
Khare, G., Duong, A., Hanotaux, J., Shorr, R., Nampoothiri, R. V., Maganti, H. B., & Allan, D. (2026) · Cytotherapy · doi:10.1016/j.jcyt.2026.102898 · Cited by 1
Recent Advancements in Gene Therapy
Kumar, S. (2026) · Springer eBooks · doi:10.1007/978-981-95-7688-3_11
Albulushi, A., Rashdi, T. A., & Al-Farhan, H. (2026) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvag013
Metadata
- Authors
- Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., Phillips, J., Xu, Y., Amaral, A., Boyd, A. P., Cehelsky, J. E., McKee, M. D., Schiermeier, A., Harari, O., Murphy, A., Kyratsous, C. A., Zambrowicz, B., Soltys, R., Gutstein, D. E., Leonard, J., Sepp-Lorenzino, L., & Lebwohl, D.
- Affiliations
- University of Auckland (NZ)
- From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George’s University of London (J.T.) — both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) — all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 493-502
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177445623
- Cited by
- 1,801
- References
- 35
- Citations by year
- 2026: 349 · 2025: 332 · 2024: 368 · 2023: 336 · 2022: 328 · 2021: 84
- FWCI
- 228.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Regeneron Pharmaceuticals
- Intellia Therapeutics
- Topics
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- transthyretin amyloidosis, hereditary ATTR amyloidosis, CRISPR/Cas9 genome editing, in vivo gene therapy, prealbumin, polyneuropathy, single ascending dose, pharmacodynamics, safety
- MeSH terms
- Gene Editing, RNA, Guide, CRISPR-Cas Systems, Female, Humans, Infusions, Intravenous, Liposomes, Male, Middle Aged, Prealbumin, RNA, Messenger, RNA, Guide, Kinetoplastida, Gene Transfer Techniques, Amyloid Neuropathies, Familial, Nanoparticles, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-27, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-27 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.



